About Provectus Biopharmaceuticals (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:PVCT
- Previous Symbol: NYSEMKT:PVCT
- CUSIP: N/A
- Web: www.provectusbio.com
- Debt-to-Equity Ratio: -0.97%
- Current Ratio: 0.13%
- Quick Ratio: 0.13%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $0.01 per share
- Price / Book: 4.10
- Trailing EPS: ($0.08)
- Net Income: ($24,420,000.00)
- Return on Equity: -2,045.29%
- Return on Assets: -334.46%
- Employees: 2
- Outstanding Shares: 370,740,000
Frequently Asked Questions for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
What is Provectus Biopharmaceuticals' stock symbol?
Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."
Who are some of Provectus Biopharmaceuticals' key competitors?
Some companies that are related to Provectus Biopharmaceuticals include Prana Biotechnology Ltd (PRAN), Tandem Diabetes Care (TNDM), Streamline Health Solutions (STRM), Trimel Pharmaceuticals Corp. (TRLPF), Tonix Pharmaceuticals Holding Corp. (TNXP), Orexigen Therapeutics (OREX), Zosano Pharma Corporation (ZSAN), Tokai Pharmaceuticals (NVUS), Cleveland BioLabs (CBLI), HTG Molecular Diagnostics (HTGM), Pain Therapeutics (PTIE), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), TrovaGene (TROV), Eleven Biotherapeutics (EBIO), Cellectar Biosciences (CLRB), Fibrocell Science (FCSC) and Kitov Pharmaceuticals Holdings (KTOV).
Who are Provectus Biopharmaceuticals' key executives?
Provectus Biopharmaceuticals' management team includes the folowing people:
- Dominic Rodrigues, Chairman of the Board
- Timothy C. Scott Ph.D., President (Age 51)
- John R. Glass CPA, Interim Chief Financial Officer (Age 72)
- Eric A. Wachter Ph.D., Chief Technology Officer, Director (Age 52)
- Bruce Horowitz, Director
- Jan E Koe, Independent Director (Age 65)
How do I buy Provectus Biopharmaceuticals stock?
Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Provectus Biopharmaceuticals' stock price today?
One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.04.
How big of a company is Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals has a market capitalization of $15.2 million. The company earns ($24,420,000.00) in net income (profit) each year or ($0.08) on an earnings per share basis. Provectus Biopharmaceuticals employs 2 workers across the globe.
How can I contact Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 865-769-4011 or via email at [email protected]
MarketBeat Community Rating for Provectus Biopharmaceuticals (OTCMKTS PVCT)MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Provectus Biopharmaceuticals (OTCMKTS:PVCT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
Analysts' Ratings History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
Earnings History by Quarter for Provectus Biopharmaceuticals (OTCMKTS PVCT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Provectus Biopharmaceuticals (OTCMKTS PVCT)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Provectus Biopharmaceuticals (OTCMKTS PVCT)
No headlines for this company have been tracked by MarketBeat.com
Provectus Biopharmaceuticals (OTCMKTS PVCT) Chart for Monday, November, 20, 2017